Cervomed INC Form 4 insider transactions

Director Joshua S. Boger acquired 955,414 units of CervoMed Inc. through a private placement, signaling significant insider confidence.

Director Frank Zavrl was granted an option to purchase 8,150 shares of CervoMed common stock following his election to the board.

Director Marwan Sabbagh was granted options to purchase 8,150 shares of CervoMed common stock following his election to the board.

Director David Quigley was granted options to purchase 8,150 shares of CervoMed Inc. common stock following his election to the board.

Director Jeffrey V. Poulton was granted 8,150 stock options as part of CervoMed Inc.'s non-employee director compensation policy.

Director Jane Hollingsworth was granted an option to purchase 8,150 shares of CervoMed common stock following her election to the board.

Director Sylvie Gregoire was granted 8,150 stock options following her election to the CervoMed Inc. board of directors.

Director Joshua Boger was granted options to purchase 8,150 shares of CervoMed common stock following his election to the board.

CervoMed Inc. CEO John J. Alam filed a Form 4 disclosing an 8,150 share stock option grant awarded to his spouse, Sylvie Gregoire.

CervoMed Inc.'s Chief Commercial and Business Officer, Matthew Winton, was granted 30,000 stock options with an exercise price of $4.80.

CervoMed Inc. reported a stock option grant of 75,000 shares to the spouse of a director and 10% owner, who is also the company's President and CEO.

CervoMed Inc.'s CFO, GC & Secretary, William Robert Elder, was granted 30,000 stock options with an exercise price of $4.80, vesting monthly over 36 months starting February 28, 2026.

CervoMed Inc. executive Mark De Rosch was granted 30,000 stock options with an exercise price of $4.80, vesting over 36 months.

CervoMed Inc.'s EVP of Clinical Development, Kelly Blackburn, was granted 30,000 stock options with an exercise price of $4.80, vesting over 36 months.

CervoMed Inc.'s CEO and President, John J. Alam, was granted 75,000 stock options with an exercise price of $4.80, vesting over 36 months.

CervoMed Inc. Director David Quigley was granted 16,200 stock options at an exercise price of $7.02, vesting over 36 months.

CervoMed Inc.'s Chief Commercial and Business Officer, Matthew Winton, purchased 5,000 shares of company common stock for a total of $41,430 in open-market transactions.

CervoMed Inc. Director and 10% owner Sylvie Gregoire acquired 21,600 shares of common stock for approximately $182,500 in open-market transactions.

CervoMed Inc.'s CFO, GC & Secretary, William Robert Elder, increased his direct ownership in the company through recent open-market stock purchases.

CervoMed Inc.'s CEO and President, John J. Alam, acquired 21,600 shares of common stock through open-market transactions on November 17, 2025.

CervoMed Inc. Director and 10% owner Sylvie Gregoire acquired 7,847 shares of common stock across multiple transactions in mid-November 2025, totaling approximately $59,094.

CervoMed Inc.'s CEO and President, John J. Alam, increased his beneficial ownership of common stock through open-market purchases in mid-November 2025.

CervoMed Inc.'s Chief Commercial and Business Officer, Matthew Winton, purchased 10,000 shares of common stock in open-market transactions.

CervoMed Inc. Director Sylvie Gregoire acquired 5,553 shares of common stock, signaling insider confidence.

CervoMed Inc.'s CFO, William Robert Elder, purchased 3,500 shares of common stock at $7.44 per share in a pre-planned open-market transaction.

CervoMed Inc.'s CEO and President, John J. Alam, acquired 5,553 shares of common stock in an open-market transaction.

CervoMed Inc. awarded Chief Commercial and Business Officer Matthew Winton 75,000 stock options as an inducement to join the company.

John J. Alam, CEO and President of CervoMed Inc., reported an indirect acquisition of 8,100 stock options granted to his spouse, Sylvie Gregoire, a non-employee director, with an exercise price of $6.52 per share.

CervoMed Inc. announced that Frank Zavrl, a newly elected director, was granted 8,100 stock options with an exercise price of $6.52, vesting monthly over one year.

CervoMed Inc. has granted 8,100 stock options to Joshua S. Boger, a newly elected director and 10% owner, as part of its non-employee director compensation policy.